There are currently 89 active clinical trials seeking participants for Asthma research studies. The states with the highest number of trials for Asthma participants are California, Texas, Florida and Ontario.
Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
NCT06020014
Recruiting
This is a Phase 2a, multicentre, randomised, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy, safety and PK of AZD4604 administered BID using a dry-powder inhaler at one dose level over a 12-week Treatment period in adult participants with uncontrolled moderate-to-severe asthma.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/14/2025
Locations: Research Site, Birmingham, Alabama +162 locations
Conditions: Asthma
Register for Updates
Longitudinal Observational Study of Severe Asthma
NCT01780142
Recruiting
Background: - Asthma is a lung condition that causes difficulty breathing and decreased lung function. Some people with asthma have more severe disease symptoms. They may be less responsive to standard treatments such as steroids. Researchers want to compare severe asthmatics with mild or moderate asthmatics or people without asthma over a long period. This information may help identify new treatments for people whose asthma is not well controlled by standard medications. Objectives: - To com... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
04/11/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Asthma
Register for Updates
Project 2 Airway Potential Hydrogen (pH) in Asthma
NCT03617718
Recruiting
This study is testing a non invasive way to measure airway pH in individuals with Asthma and Cystic Fibrosis using a new inhaled drug. The airway pH will help health care providers in creating tailored treatment plans for individuals suffering from these specific conditions.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
04/11/2025
Locations: Indiana University School of Medicine, Indianapolis, Indiana +1 locations
Conditions: Cystic Fibrosis, Asthma, Severe Persistent Asthma, Healthy
Register for Updates
Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma
NCT05251259
Recruiting
This is a randomised, placebo-controlled, double-blind study to assess the efficacy and safety of Atuliflapon administered once daily over a 12-week treatment period to adult participants with moderate to severe uncontrolled asthma.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/11/2025
Locations: Research Site, Birmingham, Alabama +391 locations
Conditions: Asthma
Register for Updates
Personalized Environment and Genes Study
NCT00341237
Recruiting
Despite the overwhelming focus on genetic and genomic causes of human disease over the past two decades, it has been estimated that genetics is currently known to explain only 20% and 40% of the etiology of common disease. Thus, it is becoming increasingly apparent that human disease is a consequence of both genetic susceptibility and environmental exposures. Importantly, while individuals cannot change their genetic composition, we do have the ability both personally and as a society, to influe... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
04/10/2025
Locations: NIEHS Clinical Research Unit (CRU), Research Triangle Park, North Carolina
Conditions: Diabetes, Heart Disease, Asthma
Register for Updates
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
NCT06932263
Recruiting
This is a dose-range finding, double-blind, placebo-controlled, phase IIb study designed to assess efficacy and safety of tozorakimab administered subcutaneously in adult participants with uncontrolled asthma receiving medium-to-high dose inhaled corticosteroids.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/09/2025
Locations: Research Site, Bakersfield, California +164 locations
Conditions: Asthma
Register for Updates
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.
NCT05763121
Recruiting
This study will assess the efficacy and safety of dexpramipexole as an adjunctive oral therapy in participants with inadequately controlled asthma with an eosinophilic phenotype and a history of asthma exacerbations.
Gender:
ALL
Ages:
Between 12 years and 99 years
Trial Updated:
04/09/2025
Locations: Research Site 20001-374, Bakersfield, California +331 locations
Conditions: Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
Register for Updates
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)
NCT05813288
Recruiting
The objective of this clinical study is to investigate the safety, tolerability, and efficacy of dexpramipexole in participants with inadequately controlled severe eosinophilic asthma.
Gender:
ALL
Ages:
Between 12 years and 99 years
Trial Updated:
04/09/2025
Locations: Research Site 30001-287, Mobile, Alabama +247 locations
Conditions: Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
Register for Updates
Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics
NCT03953300
Recruiting
The purpose of the study is to evaluate effect of benralizumab on structural and lung function changes in severe eosinophilic asthmatics. Changes will be assessed over 48 week treatment period in patients with persistent symptoms despite standard therapy of inhaled corticosteroids (ICS) plus long acting B2-agonist (LABA) with or without additional controller medication. Patients who complete treatment will enter 4 weeks follow-up period.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/09/2025
Locations: Research Site, Birmingham, Alabama +52 locations
Conditions: Asthma
Register for Updates
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma
NCT06920901
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, and immunogenicity of APG777 in adult participants with mild-to-moderate asthma. The duration of the study will be approximately 52 weeks (364 days) for each participant and will consist of a Screening Period, Treatment Period, and Follow-up Period.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/08/2025
Locations: Orso Health, La Jolla, California +9 locations
Conditions: Asthma
Register for Updates
A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma
NCT06261957
Recruiting
The goal of this study is to assess and compare the safety and tolerability of salbutamol administered via metered dose inhaler (MDI) containing propellant 1,1-difluoroethane (HFA-152a) or 1,1,1,2-tetrafluoroethane (HFA-134a) in participants aged \>=18 years with asthma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/04/2025
Locations: GSK Investigational Site, North Hollywood, California +105 locations
Conditions: Asthma
Register for Updates
Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma
NCT06102005
Recruiting
This is a Phase 2b, global, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the efficacy, safety, and tolerability of add-on therapy with SC lunsekimig in adult participants aged 18 to 80 years, (inclusive) with moderate-to-severe asthma.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/02/2025
Locations: Allergy, Asthma & Immunology Associates- Site Number : 8400009, Scottsdale, Arizona +155 locations
Conditions: Asthma
Register for Updates